
| Tradename | Company | Number | Date | Products | 
|---|---|---|---|---|
| ELYXYB | Scilex Pharmaceuticals | N-212157 RX | 2020-05-05 | 1 products, RLD, RS | 
| CELEBREX | Upjohn | N-020998 RX | 1998-12-31 | 4 products, RLD | 
| Tradename | Company | Number | Date | Products | 
|---|---|---|---|---|
| CONSENSI | Purple Biotech | N-210045 DISCN | 2018-05-31 | 3 products, RLD | 
| Brand Name | Status | Last Update | 
|---|---|---|
| celebrex | New Drug Application | 2024-11-22 | 
| celecoxib | ANDA | 2025-09-26 | 
| celecoxib 100 mg | ANDA | 2015-11-30 | 
| celecoxib 200 mg | ANDA | 2019-11-01 | 
| celecoxib 400 mg | ANDA | 2015-11-27 | 
| celecoxib 50 mg | ANDA | 2015-11-28 | 
| celecoxib celecoxib | ANDA | 2021-12-21 | 
| elyxyb | New Drug Application | 2020-05-13 | 
| elyxyb - celecoxib | New Drug Application | 2024-11-26 | 
| generic drug | ANDA | 2022-01-17 | 
| Expiration | Code | ||
|---|---|---|---|
| CELECOXIB / TRAMADOL HYDROCHLORIDE, SEGLENTIS, KOWA PHARMS | |||
| 2024-10-15 | NP | ||
| CELECOXIB, ELYXYB, SCILEX HLDG | |||
| 2023-05-05 | NP | ||
| Patent | Expires | Flag | FDA Information | 
|---|---|---|---|
| Amlodipine Besylate / Celecoxib, Consensi, Purple Biotech | |||
| 10350171 | 2038-06-14 | DP | |
| 10925835 | 2038-06-14 | U-2410 | |
| 10945960 | 2038-06-14 | DP | |
| 9408837 | 2030-02-28 | U-2410 | |
| 9662315 | 2029-05-22 | DP | U-2410 | 
| Celecoxib, Elyxyb, Scilex Hldg | |||
| 9572819 | 2036-05-27 | DP | U-2718 | 
| 9795620 | 2036-05-27 | DP | U-2718 | 
| 9949990 | 2036-05-27 | DP | U-2718 | 
| 10376527 | 2036-05-27 | DP | U-2718 | 
| 10722456 | 2036-05-27 | DP | U-2718 | 
| 10799517 | 2036-05-27 | DP | U-2718 | 
| Celecoxib / Tramadol Hydrochloride, Seglentis, Kowa Pharms | |||
| 8846744 | 2031-06-03 | DP | |
| 8598152 | 2030-04-19 | DS, DP | |
| 9012440 | 2030-04-19 | DS, DP | |
| 10238668 | 2030-04-19 | DS, DP | U-3244 | 
| 10245276 | 2030-04-19 | DS, DP | |
| 10548909 | 2030-04-19 | U-3244 | |
| 11478488 | 2030-04-19 | U-3244 | |

| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | 4 | 28 | 14 | 12 | 58 | 
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 2 | 9 | 21 | 14 | 7 | 51 | 
| Postoperative pain | D010149 | — | G89.18 | 1 | 5 | 12 | 19 | 10 | 46 | 
| Colorectal neoplasms | D015179 | — | — | 7 | 25 | 8 | 1 | 2 | 39 | 
| Healthy volunteers/patients | — | — | — | 24 | — | — | 3 | 3 | 30 | 
| Pain | D010146 | EFO_0003843 | R52 | 3 | 5 | 4 | 9 | 6 | 27 | 
| Colonic neoplasms | D003110 | — | C18 | 4 | 6 | 7 | 1 | 1 | 18 | 
| Acute pain | D059787 | — | R52 | 1 | 3 | 5 | 2 | 4 | 15 | 
| Low back pain | D017116 | — | M54.5 | — | 1 | 5 | 5 | 4 | 15 | 
| Prostatic neoplasms | D011471 | — | C61 | 1 | 10 | 2 | 1 | 2 | 14 | 
| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 10 | 18 | 3 | — | 6 | 34 | 
| Neoplasms | D009369 | — | C80 | 16 | 12 | 2 | — | 2 | 28 | 
| Non-small-cell lung carcinoma | D002289 | — | — | 8 | 16 | 3 | — | 1 | 26 | 
| Lung neoplasms | D008175 | — | C34.90 | 9 | 14 | 1 | — | 1 | 23 | 
| Head and neck neoplasms | D006258 | — | — | 4 | 12 | 1 | — | 1 | 15 | 
| Rectal neoplasms | D012004 | — | — | 2 | 8 | 3 | — | 1 | 14 | 
| Chronic pain | D059350 | — | — | — | 1 | 4 | — | 2 | 7 | 
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | 1 | 7 | 1 | — | — | 7 | 
| Adenomatous polyposis coli | D011125 | — | D13.91 | 1 | 3 | 3 | — | 1 | 7 | 
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | 4 | 2 | — | — | 5 | 
| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 7 | 4 | — | — | 1 | 11 | 
| Carcinoma | D002277 | — | C80.0 | 2 | 6 | — | — | 1 | 8 | 
| Esophageal neoplasms | D004938 | — | C15 | 3 | 5 | — | — | — | 8 | 
| Recurrence | D012008 | — | — | 2 | 6 | — | — | — | 7 | 
| Melanoma | D008545 | — | — | 5 | 3 | — | — | 1 | 7 | 
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | 4 | — | — | — | 6 | 
| Central nervous system neoplasms | D016543 | — | — | — | 6 | — | — | — | 6 | 
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 4 | — | — | 2 | 6 | 
| Covid-19 | D000086382 | — | U07.1 | — | 4 | — | — | 1 | 5 | 
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 5 | — | — | — | 5 | 
| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Germ cell and embryonal neoplasms | D009373 | — | — | 3 | — | — | — | — | 3 | 
| Mesothelioma | D008654 | — | C45 | 3 | — | — | — | — | 3 | 
| Myeloproliferative disorders | D009196 | — | D47.1 | 2 | — | — | — | — | 2 | 
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | 1 | 2 | 
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 | 
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | 1 | 2 | 
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | 1 | 2 | 
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 2 | — | — | — | — | 2 | 
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | 1 | 2 | 
| Macular edema | D008269 | — | — | 2 | — | — | — | — | 2 | 
| Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total | 
|---|---|---|---|---|---|---|---|---|---|
| Heterotopic ossification | D009999 | — | — | — | — | — | — | 2 | 2 | 
| Cachexia | D002100 | — | R64 | — | — | — | — | 2 | 2 | 
| Dementia | D003704 | EFO_0003862 | F03 | — | — | — | — | 2 | 2 | 
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | — | — | — | 1 | 1 | 
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | — | — | — | 1 | 1 | 
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | — | 1 | 1 | 
| Papillomaviridae | D027383 | — | — | — | — | — | — | 1 | 1 | 
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | — | — | — | 1 | 1 | 
| Hemorrhoids | D006484 | EFO_0009552 | K64 | — | — | — | — | 1 | 1 | 
| Shoulder injuries | D000070599 | — | — | — | — | — | — | 1 | 1 | 
| Drug common name | Celecoxib | 
| INN | celecoxib | 
| Description | Celecoxib is a member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-sulfamoylphenyl, trifluoromethyl and p-tolyl groups, respectively. A cyclooxygenase-2 inhibitor, it is used in the treatment of arthritis. It has a role as a cyclooxygenase 2 inhibitor, a geroprotector, a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. It is a member of toluenes, a sulfonamide, a member of pyrazoles and an organofluorine compound. | 
| Classification | Small molecule | 
| Drug class | cyclooxygenase-2 inhibitors | 
| Image (chem structure or protein) |  | 
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1 | 
| PDB | — | 
| CAS-ID | 169590-42-5 | 
| RxCUI | — | 
| ChEMBL ID | CHEMBL118 | 
| ChEBI ID | 41423 | 
| PubChem CID | 2662 | 
| DrugBank | DB00482 | 
| UNII ID | JCX84Q7J1L (ChemIDplus, GSRS) | 












